What's Happening?
Bristol Myers Squibb and Pfizer have announced a collaboration with Mark Cuban Cost Plus Drug Company to make Eliquis, a widely prescribed oral anticoagulant, available on CostPlusDrugs.com. Starting April 27, 2026, patients with a prescription can purchase
a 30-day supply of Eliquis for $345. This initiative aims to provide cash-paying patients with a more affordable option to access Eliquis, which is used to reduce the risk of stroke and blood clots in patients with atrial fibrillation and to treat deep vein thrombosis and pulmonary embolism. The collaboration is part of the BMS-Pfizer Alliance's efforts to expand direct-to-patient options and overcome access barriers.
Why It's Important?
This collaboration is significant as it addresses the high cost of prescription medications in the U.S., providing a more affordable option for patients who pay out-of-pocket. Eliquis is a critical medication for millions of Americans, and reducing its cost can lead to better adherence to treatment regimens, potentially reducing healthcare costs associated with hospitalizations and complications from untreated conditions. The partnership with Mark Cuban Cost Plus Drug Company highlights a growing trend towards transparency and cost reduction in the pharmaceutical industry, which could influence other companies to adopt similar models.
What's Next?
The success of this collaboration could lead to further partnerships between pharmaceutical companies and cost-reduction platforms, potentially expanding the range of medications available at reduced prices. Stakeholders, including healthcare providers and patient advocacy groups, may push for similar initiatives to improve medication access and affordability. Monitoring the impact on patient outcomes and healthcare costs will be crucial in assessing the long-term viability of such collaborations.
